Regen Biopharma (OTCMKTS:RGBP) Stock Resumes The Uptrend: Are You Excited?
The Regen Biopharma (OTCMKTS:RGBP) stock seems to have come into favor among many investors this week. Over the course of the past week, the Regen stock has been in the middle of a strong rally and has managed to clock gains of as much as 30%.
In light of such handsome gains, it is perhaps time for investors to take a closer look at the company and particularly at some of the recent developments. Yesterday the company released information with regards to the discussion about Regen Biopharma’s financial situation. The company revealed as of September 30, 2020, it had a cash balance of $0 but at the same time in 2019, its cash balance stood at $7885. The reduction in the cash balance was primarily down to the expenses incurred towards funding the operations of Regen.
In this regard, the company also revealed that it had an account receivable-related party to the tune of $71,186 as of September 30, 2019. On the other hand, the same figure on September 30, 2020, came in at $103192. On the other hand, it is also important to point out that the rise was also fuelled by the fact that the company got anniversary fees as well as royalties to the tune of $27424 from Zander at the end of each quarter.
Hence, it is clear to see that situation at the company may be improving and that might be one of the reasons behind the rally in the stock over the past week.
Regen BioPharma (RGBP) Stock Extends Jump on Heavy Volume: Are You Excited?
Those who are currently looking into major gainers in the biotech sector in recent days could consider taking a look at the Regen BioPharma Inc (OTCMKTS:RGBP) stock. This past week, the stock was in considerable focus among investors and managed to clock gains of as much as 51% through the week. The stock is up another 38% to $0.031 in the opening session on Tuesday.
The stock had really come into the attention of investors earlier this year in April when the company along with its subsidiary company KLS signed a licensing deal with Oncology Pharma Inc. As part of this agreement, Regen will be able to deploy some of the intellectual properties owned by Oncology Pharma for the development of treatments for pancreatic cancer. The licensing agreement is going to be in place for 15 years.
However, that is not all. There are certain other things that need to be kept in mind with regards to Regen BioPharma as well. At this point in time, the company is working on preparing its filings and eventually making the submissions so that it can get pink current status on the OTC Markets.
Once it gets that designation, the stock is expected to be even more attractive for many investors. The Regen stock has made a powerful move up the charts over the course of recent days and it is believed that it is on track to make similar moves that had been seen in some of the other micro-cap stocks like Tesoro and Enzolytics in recent months.